samedan logo
 
 
 
spacer
home > ebr > summer 2021 > accelerating ov immunotherapeutic innovation to market
PUBLICATIONS
European Biopharmaceutical Review

Accelerating OV Immunotherapeutic Innovation to Market

Leveraging the process and analytical expertise of specialised external CDMO partners early in development of oncolytic viruses (OVs) has become a beneficial strategy in providing additional capabilities and insights for many biotech companies approaching this type of cancer treatment.

What science and capabilities are key to creating OVs with safe, efficacious, and robust processes to produce OV programmes? Why it is critical to find specialised commercial partners, and how is best to engage them in the dynamic sector of oncological immunotherapeutic science?

Global spending on cancer therapies and supportive care drugs is expected to reach $200 billion by 2022 (1). With an estimated 18 million cancer cases around the world in 2018, cancer is a leading cause of death and has become an enormous social burden (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Before Vibalogics, Kai Lipinski PhD served as Principal Scientist at Cobra Biologics, focusing on upstream process development for virus and mammalian protein expression projects. Prior to that, Kai worked as Senior Principal Scientist at ML Laboratories, where he was responsible for the development of targeted adenoviral vectors for cancer gene therapy approaches. As Chief Scientific Officer at Vibalogics, Kai is central to the establishment of virus process development and manufacturing capabilities, technical developments, and the acquisition of many key clients.

Kai has a PhD in Transcriptional Regulation by Adenoviral E1A Proteins, and a Post-Doctorate, also on Transcriptional Regulation, from the University of Duisburg-Essen, Germany
spacer
Kai Lipinski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement